Stay updated on GeneNews LimitedPress Releases

Sign up to get notified when there's something new on the GeneNews LimitedPress Releases page.
Latest website image capture
Clouds background image

Latest updates to the GeneNews LimitedPress Releases page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    8 days ago
    Change Detected
    Summary
    The website now includes new data for Genentech's Susvimo demonstrating sustained efficacy in two serious diabetic eye conditions, which is likely to be of interest to users monitoring updates on the website.
    Difference
    7%
    Check dated 2024-07-19T09:27:31.000Z thumbnail image
  7. Check
    9 days ago
    Change Detected
    Summary
    The website now includes information about Genentech’s Vabysmo showing extended durability, continued efficacy, and a consistent safety profile in a long-term study on Diabetic Macular Edema (DME), while the previous information about FDA approving Genentech's Alecensa as the first adjuvant treatment for ALK-Positive Early-Stage Lung Cancer has been removed.
    Difference
    8%
    Check dated 2024-07-18T07:42:35.000Z thumbnail image
  8. Check
    10 days ago
    Change Detected
    Summary
    Genentech announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity, a significant development compared to the previous data on Ocrevus for MS patients.
    Difference
    10%
    Check dated 2024-07-17T07:24:34.000Z thumbnail image
  9. Check
    16 days ago
    Change Detected
    Summary
    The website has made changes to its privacy choices.
    Difference
    0.6%
    Check dated 2024-07-11T01:00:01.000Z thumbnail image
  10. Check
    18 days ago
    Change Detected
    Summary
    Genentech is reintroducing Susvimo for people with Wet Age-Related Macular Degeneration, marking a significant update on the website.
    Difference
    8%
    Check dated 2024-07-08T23:04:29.000Z thumbnail image
  11. Check
    21 days ago
    Change Detected
    Summary
    FDA approves Genentech’s Vabysmo Prefilled Syringe for three leading causes of vision loss, adding 422 new results.
    Difference
    8%
    Check dated 2024-07-05T17:54:12.000Z thumbnail image

Stay in the know with updates to GeneNews LimitedPress Releases

Enter your email address, and we'll notify you when there's something new on the GeneNews LimitedPress Releases page.